Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TPI1 | P60174 | 1/20 | 0.31 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.30 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.30 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783396 | 0.80 | PPARD (0.39) | BTN3A1PPARDLPAR3LPAR1LPAR2 | |
| Methacrylic Acid SCHEMBL1877845 | 0.80 | PEPD (0.41) | BTN3A1PPARDLPAR3LPAR1LPAR2 | |
| SCHEMBL1072477 | 0.79 | THRB (0.37) | BTN3A1PPARDLPAR3LPAR1LPAR2 | |
| Methacrylic Acid SCHEMBL27796761 | 0.79 | PEPD (0.40) | BTN3A1PPARDLPAR3LPAR1LPAR2 | |
| SCHEMBL5145800 | 0.76 | THRB (0.42) | BTN3A1PPARDLPAR3LPAR1LPAR2 | |
| Ethylene SCHEMBL790436 | 0.75 | — | — | |
| Ethylene SCHEMBL17060515 | 0.75 | TSHR (0.50) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL40792 | 0.74 | — | — | |
| SCHEMBL27666183 | 0.74 | TSHR (0.56) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10426861 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024123791-A1 | FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2023-11-30 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4146168-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4029510-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-2558538-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Oligasis (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2512462-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | Oligasis (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011130694-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011075185-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075736-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | OLIGASIS CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| EP-1988910-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | Oligasis Corporation (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100905-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | NEXGEN THERAPEUTICS, LLC (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100902-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | OLIGASIS CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | BTN3A1 199/4885PPARD 4717/4885LPAR3 38/4885 |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | CFD, CFH, CFB | BTN3A1 1460/4885PPARD 1827/4885LPAR3 1033/4885 |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | PHOSPHO1, EPHA2, PCTP | BTN3A1 1715/4885PPARD 4442/4885LPAR3 9/4885 |
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | PHOSPHO1, PCTP, SGMS1 | BTN3A1 1879/4885PPARD 4381/4885LPAR3 74/4885 |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | IL6, FLT4, TEK | BTN3A1 840/4885PPARD 4118/4885LPAR3 2953/4885 |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | BTN3A1 199/4885PPARD 4717/4885LPAR3 38/4885 |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | PHOSPHO1, MSN, ZW10 | BTN3A1 199/4885PPARD 4717/4885LPAR3 38/4885 |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | CFD, CFH, CFB | BTN3A1 1460/4885PPARD 1827/4885LPAR3 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.